Literature DB >> 34697186

The Association Between Hot Flashes and Renal Dysfunction After Androgen Deprivation Therapy With Radiotherapy in Japanese Patients With High-risk Prostate Cancer.

Hiroshi Masuda1, Kosuke Mikami2, Kotaro Otsuka2, Kyokusin Hou2, Takahito Suyama2, Kazuhiro Araki2, Satoko Kojima2, Yukio Naya2.   

Abstract

BACKGROUND/AIM: We investigated the changes in and characteristics of renal function in Japanese patients with high-risk prostate cancer (PCa) who underwent radiotherapy and long-term androgen deprivation therapy (ADT), including those seen after the ADT was discontinued. PATIENTS AND METHODS: Among 60 patients who were pathologically diagnosed with PCa and received ADT for 24 months and radiotherapy, 36 patients who underwent treatment for stage B or C PCa were eligible. We assessed renal function using the estimated glomerular filtration rate (eGFR) and investigated the rate of change in the eGFR (ΔeGFR) during and after ADT. Univariate and multivariate logistic analyses were carried out to identify clinical factors that were significantly associated with renal dysfunction at 36 months.
RESULTS: The incidence of renal dysfunction at 36 months was 75% (27/36). Multivariate analysis showed that the presence/absence of HF was an independent predictor of renal dysfunction at 36 months.
CONCLUSION: Renal function tended to recover after ADT was received for 24 months and subsequently discontinued. The presence/absence of HF represents new and meaningful information for patients receiving ADT, and high-risk PCa patients prior to ADT.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  ADT; High-risk prostate cancer; estimated glomerular filtration rate; hot flashes; renal dysfunction

Mesh:

Substances:

Year:  2021        PMID: 34697186      PMCID: PMC8627764          DOI: 10.21873/invivo.12650

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  20 in total

1.  The Relationship between Hot Flashes and Testosterone Recovery after 12 Months of Androgen Suppression for Men with Localised Prostate Cancer in the ASCENDE-RT Trial.

Authors:  M Dosani; W J Morris; S Tyldesley; T Pickles
Journal:  Clin Oncol (R Coll Radiol)       Date:  2017-07-13       Impact factor: 4.126

2.  Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?

Authors:  Nancy L Keating; A James O'Malley; Stephen J Freedland; Matthew R Smith
Journal:  Eur Urol       Date:  2012-04-19       Impact factor: 20.096

3.  NCCN clinical practice guidelines in oncology: prostate cancer.

Authors:  James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

Review 4.  Androgen deprivation therapy: evidence-based management of side effects.

Authors:  Hamed Ahmadi; Siamak Daneshmand
Journal:  BJU Int       Date:  2013-01-25       Impact factor: 5.588

Review 5.  Androgen deprivation therapy for prostate cancer.

Authors:  Nima Sharifi; James L Gulley; William L Dahut
Journal:  JAMA       Date:  2005-07-13       Impact factor: 56.272

6.  Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

Authors:  Milena Braga-Basaria; Adrian S Dobs; Denis C Muller; Michael A Carducci; Majnu John; Josephine Egan; Shehzad Basaria
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

7.  Androgen deprivation therapy in the treatment of advanced prostate cancer.

Authors:  Mark A Perlmutter; Herbert Lepor
Journal:  Rev Urol       Date:  2007

Review 8.  Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.

Authors:  Shehzad Basaria
Journal:  J Androl       Date:  2008-06-20

9.  Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.

Authors:  Francesco Lapi; Laurent Azoulay; M Tamim Niazi; Hui Yin; Serge Benayoun; Samy Suissa
Journal:  JAMA       Date:  2013-07-17       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.